Palvella Therapeutics (PVLA) Competitors $23.00 -0.23 (-0.99%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock PVLA vs. PAHC, COLL, RCUS, SYRE, PHVS, AVDL, NTLA, CMRX, CDMO, and SNDXShould you be buying Palvella Therapeutics stock or one of its competitors? The main competitors of Palvella Therapeutics include Phibro Animal Health (PAHC), Collegium Pharmaceutical (COLL), Arcus Biosciences (RCUS), Spyre Therapeutics (SYRE), Pharvaris (PHVS), Avadel Pharmaceuticals (AVDL), Intellia Therapeutics (NTLA), Chimerix (CMRX), Avid Bioservices (CDMO), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry. Palvella Therapeutics vs. Phibro Animal Health Collegium Pharmaceutical Arcus Biosciences Spyre Therapeutics Pharvaris Avadel Pharmaceuticals Intellia Therapeutics Chimerix Avid Bioservices Syndax Pharmaceuticals Phibro Animal Health (NASDAQ:PAHC) and Palvella Therapeutics (NASDAQ:PVLA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Does the MarketBeat Community favor PAHC or PVLA? Phibro Animal Health received 302 more outperform votes than Palvella Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Palvella Therapeutics an outperform vote while only 59.81% of users gave Phibro Animal Health an outperform vote. CompanyUnderperformOutperformPhibro Animal HealthOutperform Votes31759.81% Underperform Votes21340.19% Palvella TherapeuticsOutperform Votes15100.00% Underperform VotesNo Votes Which has better earnings and valuation, PAHC or PVLA? Phibro Animal Health has higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhibro Animal Health$1.19B0.79$2.42M$0.7829.81Palvella Therapeutics$42.81M5.93-$24.54M-$12.10-1.90 Do analysts recommend PAHC or PVLA? Phibro Animal Health presently has a consensus price target of $20.00, indicating a potential downside of 13.98%. Palvella Therapeutics has a consensus price target of $46.29, indicating a potential upside of 101.24%. Given Palvella Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Palvella Therapeutics is more favorable than Phibro Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phibro Animal Health 2 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Palvella Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the media refer more to PAHC or PVLA? In the previous week, Palvella Therapeutics had 6 more articles in the media than Phibro Animal Health. MarketBeat recorded 13 mentions for Palvella Therapeutics and 7 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.57 beat Palvella Therapeutics' score of 0.81 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Palvella Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in PAHC or PVLA? 99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Comparatively, 20.5% of Palvella Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk and volatility, PAHC or PVLA? Phibro Animal Health has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Palvella Therapeutics has a beta of 0.1, meaning that its stock price is 90% less volatile than the S&P 500. Is PAHC or PVLA more profitable? Phibro Animal Health has a net margin of 1.75% compared to Palvella Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 25.35% beat Palvella Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Phibro Animal Health1.75% 25.35% 6.21% Palvella Therapeutics N/A -80.93%-59.55% SummaryPhibro Animal Health beats Palvella Therapeutics on 12 of the 19 factors compared between the two stocks. Get Palvella Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PVLA vs. The Competition Export to ExcelMetricPalvella TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$253.99M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-1.908.9226.8419.71Price / Sales5.93250.96391.39116.98Price / CashN/A65.8538.2534.62Price / Book1.066.466.794.50Net Income-$24.54M$143.98M$3.23B$248.18M7 Day Performance5.99%3.04%4.07%1.14%1 Month Performance-9.63%7.44%12.52%15.18%1 Year PerformanceN/A-2.46%16.83%6.55% Palvella Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PVLAPalvella Therapeutics3.8145 of 5 stars$23.00-1.0%$46.29+101.2%N/A$253.99M$42.81M-1.90N/AEarnings ReportAnalyst RevisionPAHCPhibro Animal Health3.5291 of 5 stars$23.36-5.0%$20.00-14.4%+32.1%$946.15M$1.11B48.671,860Positive NewsCOLLCollegium Pharmaceutical4.0712 of 5 stars$29.07-2.4%$43.80+50.7%-12.3%$934.08M$664.28M12.53210News CoveragePositive NewsRCUSArcus Biosciences3.5699 of 5 stars$8.56-1.3%$25.67+199.8%-47.4%$906.38M$141M-2.72500Positive NewsGap DownSYRESpyre Therapeutics2.3372 of 5 stars$14.80+0.3%$53.40+260.8%-58.2%$892.09M$890,000.00-1.98100Positive NewsGap DownPHVSPharvaris1.2909 of 5 stars$16.07-0.2%$40.67+153.1%-16.5%$840.30MN/A-5.7430AVDLAvadel Pharmaceuticals2.2178 of 5 stars$8.53-5.5%$19.43+127.8%-40.3%$824.25M$169.12M-10.8070NTLAIntellia Therapeutics4.6481 of 5 stars$7.88-5.3%$36.90+368.3%-62.6%$816.23M$45.57M-1.45600Analyst ForecastCMRXChimerix0.5605 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212,000.00-9.0990Analyst ForecastCDMOAvid Bioservices0.8028 of 5 stars$12.50+0.1%$12.25-2.0%+34.6%$799.18M$139.91M-5.23320High Trading VolumeSNDXSyndax Pharmaceuticals3.8418 of 5 stars$9.28-8.9%$35.91+287.0%-47.8%$798.52M$43.72M-2.56110Positive News Related Companies and Tools Related Companies PAHC Competitors COLL Competitors RCUS Competitors SYRE Competitors PHVS Competitors AVDL Competitors NTLA Competitors CMRX Competitors CDMO Competitors SNDX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PVLA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palvella Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Palvella Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PVLA Stock Free PVLA Stock Alerts